{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Digestive+System+Neuroendocrine+Carcinoma&page=3",
    "query": {
      "condition": "Unresectable Digestive System Neuroendocrine Carcinoma",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 56,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Digestive+System+Neuroendocrine+Carcinoma&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Digestive+System+Neuroendocrine+Carcinoma&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T09:24:41.332Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03736720",
      "title": "Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Digestive System Neuroendocrine Carcinoma",
        "Locally Advanced Pancreatic Neuroendocrine Carcinoma",
        "Metastatic Digestive System Neuroendocrine Carcinoma",
        "Metastatic Pancreatic Neuroendocrine Carcinoma",
        "Refractory Digestive System Neuroendocrine Carcinoma",
        "Refractory Pancreatic Neuroendocrine Carcinoma",
        "Unresectable Digestive System Neuroendocrine Carcinoma",
        "Unresectable Pancreatic Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Liposomal Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-06-17",
      "completion_date": "2024-08-26",
      "has_results": true,
      "last_update_posted_date": "2025-01-30",
      "last_synced_at": "2026-10-06T09:24:41.332Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Stony Brook, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03736720"
    },
    {
      "nct_id": "NCT00096083",
      "title": "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "isolated perfusion",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Delcath Systems Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2004-09",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2013-10-23",
      "last_synced_at": "2026-10-06T09:24:41.332Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096083"
    },
    {
      "nct_id": "NCT03799003",
      "title": "A Study of ASP1951 in Subjects With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ASP1951",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2019-01-14",
      "completion_date": "2023-07-06",
      "has_results": false,
      "last_update_posted_date": "2024-11-01",
      "last_synced_at": "2026-10-06T09:24:41.332Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Sacramento, California • Gainesville, Florida + 15 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03799003"
    },
    {
      "nct_id": "NCT05592626",
      "title": "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Genital Neoplasm, Female",
        "Urogenital Neoplasms",
        "Lung Neoplasm",
        "Neoplasms by Site",
        "Papillomavirus Infection",
        "Epstein-Barr Virus Infections",
        "Carcinoma",
        "Neoplasms",
        "Vulvar Neoplasms",
        "Vulvar Diseases",
        "Abdominal Neoplasm",
        "NSCLC (Non-small Cell Lung Cancer)",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "STAR0602",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan (Camptosar)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Docetaxel (Taxotere)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Marengo Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 366,
      "start_date": "2023-01-04",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-06T09:24:41.332Z",
      "location_count": 13,
      "location_summary": "Sacramento, California • Celebration, Florida • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05592626"
    },
    {
      "nct_id": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Cancer",
        "Cutaneous Melanoma",
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "AU-007",
          "type": "DRUG"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aulos Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2022-04-04",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-06T09:24:41.332Z",
      "location_count": 10,
      "location_summary": "Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05267626"
    },
    {
      "nct_id": "NCT01365169",
      "title": "Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malignant Head and Neck Neoplasm",
        "Malignant Neoplasm",
        "Metastatic Malignant Neoplasm in the Neck",
        "Metastatic Malignant Neoplasm in the Uterine Cervix",
        "Pancreatic Adenocarcinoma",
        "Pancreatic Neuroendocrine Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Stage I Colorectal Cancer AJCC v6 and v7",
        "Stage I Hypopharyngeal Carcinoma AJCC v7",
        "Stage I Major Salivary Gland Cancer AJCC v7",
        "Stage I Nasopharyngeal Carcinoma AJCC v7",
        "Stage I Oral Cavity Cancer AJCC v6 and v7",
        "Stage I Oropharyngeal Carcinoma AJCC v6 and v7",
        "Stage II Colorectal Cancer AJCC v7",
        "Stage II Hypopharyngeal Carcinoma AJCC v6 and v7",
        "Stage II Major Salivary Gland Cancer AJCC v7",
        "Stage II Nasopharyngeal Carcinoma AJCC v7",
        "Stage II Oral Cavity Cancer AJCC v6 and v7",
        "Stage II Oropharyngeal Carcinoma AJCC v6 and v7",
        "Stage IIA Colorectal Cancer AJCC v7",
        "Stage IIB Colorectal Cancer AJCC v7",
        "Stage IIC Colorectal Cancer AJCC v7",
        "Stage III Colorectal Cancer AJCC v7",
        "Stage III Hypopharyngeal Carcinoma AJCC v7",
        "Stage III Laryngeal Cancer AJCC v6 and v7",
        "Stage III Major Salivary Gland Cancer AJCC v7",
        "Stage III Nasopharyngeal Carcinoma AJCC v7",
        "Stage III Oral Cavity Cancer AJCC v6 and v7",
        "Stage III Oropharyngeal Carcinoma AJCC v7",
        "Stage IIIA Colorectal Cancer AJCC v7",
        "Stage IIIB Colorectal Cancer AJCC v7",
        "Stage IIIC Colorectal Cancer AJCC v7",
        "Stage IV Colorectal Cancer AJCC v7",
        "Stage IVA Colorectal Cancer AJCC v7",
        "Stage IVA Hypopharyngeal Carcinoma AJCC v7",
        "Stage IVA Laryngeal Cancer AJCC v7",
        "Stage IVA Major Salivary Gland Cancer AJCC v7",
        "Stage IVA Nasopharyngeal Carcinoma AJCC v7",
        "Stage IVA Oral Cavity Cancer AJCC v6 and v7",
        "Stage IVA Oropharyngeal Carcinoma AJCC v7",
        "Stage IVB Colorectal Cancer AJCC v7",
        "Stage IVB Hypopharyngeal Carcinoma AJCC v7",
        "Stage IVB Laryngeal Cancer AJCC v7",
        "Stage IVB Major Salivary Gland Cancer AJCC v7",
        "Stage IVB Nasopharyngeal Carcinoma AJCC v7",
        "Stage IVB Oral Cavity Cancer AJCC v6 and v7",
        "Stage IVB Oropharyngeal Carcinoma AJCC v7",
        "Metastatic or Locally Unresectable Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Exercise Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health Telemonitoring",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 590,
      "start_date": "2011-05-25",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-10-06T09:24:41.332Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01365169"
    },
    {
      "nct_id": "NCT00003907",
      "title": "Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "mitomycin",
          "type": "DRUG"
        },
        {
          "name": "embolization",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "1999-12-15",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2023-07-05",
      "last_synced_at": "2026-10-06T09:24:41.332Z",
      "location_count": 37,
      "location_summary": "Fort Collins, Colorado • Jacksonville, Florida • Atlanta, Georgia + 18 more",
      "locations": [
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Aurora",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003907"
    },
    {
      "nct_id": "NCT02159989",
      "title": "Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Fibrolamellar Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Ovarian Carcinoma",
        "Pancreatic Neuroendocrine Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Refractory Malignant Solid Neoplasm",
        "Unresectable Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        },
        {
          "name": "Ziv-Aflibercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2014-06-18",
      "completion_date": "2024-01-29",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-06T09:24:41.332Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02159989"
    },
    {
      "nct_id": "NCT05269381",
      "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage III Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IV Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage IVA Gastric Cancer AJCC v8",
        "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IVB Gastric Cancer AJCC v8",
        "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Locally Advanced Cervical Carcinoma",
        "Locally Advanced Endometrial Carcinoma",
        "Locally Advanced Gastric Adenocarcinoma",
        "Locally Advanced Gastroesophageal Junction Adenocarcinoma",
        "Locally Advanced Head and Neck Squamous Cell Carcinoma",
        "Locally Advanced Hepatocellular Carcinoma",
        "Locally Advanced Lung Non-Small Cell Carcinoma",
        "Locally Advanced Malignant Solid Neoplasm",
        "Locally Advanced Melanoma",
        "Locally Advanced Merkel Cell Carcinoma",
        "Locally Advanced Renal Cell Carcinoma",
        "Locally Advanced Skin Squamous Cell Carcinoma",
        "Locally Advanced Triple-Negative Breast Carcinoma",
        "Locally Advanced Unresectable Breast Carcinoma",
        "Locally Advanced Unresectable Cervical Carcinoma",
        "Locally Advanced Unresectable Gastric Adenocarcinoma",
        "Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Locally Advanced Unresectable Renal Cell Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Cervical Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Gastric Adenocarcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Hepatocellular Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Merkel Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Metastatic Skin Squamous Cell Carcinoma",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Skin Squamous Cell Carcinoma",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IIIA Cervical Cancer AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIA Uterine Corpus Cancer AJCC v8",
        "Stage IIIB Cervical Cancer AJCC v8",
        "Stage IIIB Hepatocellular Carcinoma AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIB Uterine Corpus Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IIIC Uterine Corpus Cancer AJCC v8",
        "Stage IIIC1 Uterine Corpus Cancer AJCC v8",
        "Stage IIIC2 Uterine Corpus Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8",
        "Triple-Negative Breast Carcinoma",
        "Unresectable Cervical Carcinoma",
        "Unresectable Endometrial Carcinoma",
        "Unresectable Gastric Adenocarcinoma",
        "Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Unresectable Head and Neck Squamous Cell Carcinoma",
        "Unresectable Hepatocellular Carcinoma",
        "Unresectable Lung Non-Small Cell Carcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Melanoma",
        "Unresectable Merkel Cell Carcinoma",
        "Unresectable Renal Cell Carcinoma",
        "Unresectable Skin Squamous Cell Carcinoma",
        "Unresectable Triple-Negative Breast Carcinoma",
        "Unresectable Urothelial Carcinoma",
        "Breast Adenocarcinoma",
        "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Invasive Breast Lobular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Neoantigen Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2022-03-31",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-06T09:24:41.332Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05269381"
    },
    {
      "nct_id": "NCT00019786",
      "title": "Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Islet Cell Tumor",
        "Liver Cancer",
        "Metastatic Cancer",
        "Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "isolated perfusion",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 67,
      "start_date": "1999-08",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2012-03-23",
      "last_synced_at": "2026-10-06T09:24:41.332Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019786"
    }
  ]
}